Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

345

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Insulin Glargine (HOE901)/NPH Insulin

"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time~Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician~The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.~The dose adjustments will be based on the results of self-monitoring."

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY